Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies

Philippe Moreau; Thierry Facon; Saad Z. Usmani; Meletios Dimopoulos; Shaji Kumar; Torben Plesner; Hartmut Goldschmidt; Donna Reece; Robert Z. Orlowski; Aurore Perrot; Merav Leiba; Ajai Chari; Jesus San-Miguel; Gordon Cook; Shinsuke Iida; Huiling Pei; Rian Van Rampelbergh; Clarissa M. Uhlar; Thomas Renaud; Jon Ukropec; Rachel Kobos; Nizar Bahlis

doi:10.1016/S2152-2650(20)30491-2

Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies

Philippe Moreau, Thierry Facon, Saad Z. Usmani, Meletios Dimopoulos, Shaji Kumar, Torben Plesner, Hartmut Goldschmidt, Donna Reece, Robert Z. Orlowski, Aurore Perrot, Merav Leiba, Ajai Chari, Jesus San-Miguel, Gordon Cook, Shinsuke Iida, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Thomas Renaud, Jon UkropecRachel Kobos, Nizar Bahlis

IRS - Sygehus Lillebælt, Forskningsenhed for Hæmatologi (Vejle)

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	MM-339
Tidsskrift	Clinical Lymphoma Myeloma and Leukemia
Vol/bind	20
Udgave nummer	1 supplement
Sider (fra-til)	S306-S307
ISSN	2152-2650
DOI	https://doi.org/10.1016/S2152-2650(20)30491-2
Status	Udgivet - sep. 2020
Begivenhed	Society of Hematologic Oncology 2020 Annual Meeting: Virtual event - Varighed: 9. sep. 2020 → 12. sep. 2020

Konference

Konference	Society of Hematologic Oncology 2020 Annual Meeting
Periode	09/09/2020 → 12/09/2020

Dokumenter og links

10.1016/S2152-2650(20)30491-2

Citationsformater

Moreau, P., Facon, T., Usmani, S. Z., Dimopoulos, M., Kumar, S., Plesner, T., Goldschmidt, H., Reece, D., Orlowski, R. Z., Perrot, A., Leiba, M., Chari, A., San-Miguel, J., Cook, G., Iida, S., Pei, H., Van Rampelbergh, R., Uhlar, C. M., Renaud, T., ... Bahlis, N. (2020). Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies. Clinical Lymphoma Myeloma and Leukemia, 20(1 supplement), S306-S307. Artikel MM-339. https://doi.org/10.1016/S2152-2650(20)30491-2

@article{c4a0a2f2da5e4fb6a7efc319bebc9da8,

title = "Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies",

keywords = "multiple myeloma, MM, daratumumab, newly diagnosed multiple myeloma, lenalidomide discontinuation",

author = "Philippe Moreau and Thierry Facon and Usmani, {Saad Z.} and Meletios Dimopoulos and Shaji Kumar and Torben Plesner and Hartmut Goldschmidt and Donna Reece and Orlowski, {Robert Z.} and Aurore Perrot and Merav Leiba and Ajai Chari and Jesus San-Miguel and Gordon Cook and Shinsuke Iida and Huiling Pei and {Van Rampelbergh}, Rian and Uhlar, {Clarissa M.} and Thomas Renaud and Jon Ukropec and Rachel Kobos and Nizar Bahlis",

year = "2020",

month = sep,

doi = "10.1016/S2152-2650(20)30491-2",

language = "English",

volume = "20",

pages = "S306--S307",

journal = "Clinical Lymphoma Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "1 supplement",

note = "Society of Hematologic Oncology 2020 Annual Meeting ; Conference date: 09-09-2020 Through 12-09-2020",

}

Moreau, P, Facon, T, Usmani, SZ, Dimopoulos, M, Kumar, S, Plesner, T, Goldschmidt, H, Reece, D, Orlowski, RZ, Perrot, A, Leiba, M, Chari, A, San-Miguel, J, Cook, G, Iida, S, Pei, H, Van Rampelbergh, R, Uhlar, CM, Renaud, T, Ukropec, J, Kobos, R & Bahlis, N 2020, 'Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies', Clinical Lymphoma Myeloma and Leukemia, bind 20, nr. 1 supplement, MM-339, s. S306-S307. https://doi.org/10.1016/S2152-2650(20)30491-2

Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies. / Moreau, Philippe; Facon, Thierry; Usmani, Saad Z. et al.
I: Clinical Lymphoma Myeloma and Leukemia, Bind 20, Nr. 1 supplement, MM-339, 09.2020, s. S306-S307.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies

AU - Moreau, Philippe

AU - Facon, Thierry

AU - Usmani, Saad Z.

AU - Dimopoulos, Meletios

AU - Kumar, Shaji

AU - Plesner, Torben

AU - Goldschmidt, Hartmut

AU - Reece, Donna

AU - Orlowski, Robert Z.

AU - Perrot, Aurore

AU - Leiba, Merav

AU - Chari, Ajai

AU - San-Miguel, Jesus

AU - Cook, Gordon

AU - Iida, Shinsuke

AU - Pei, Huiling

AU - Van Rampelbergh, Rian

AU - Uhlar, Clarissa M.

AU - Renaud, Thomas

AU - Ukropec, Jon

AU - Kobos, Rachel

AU - Bahlis, Nizar

PY - 2020/9

Y1 - 2020/9

KW - multiple myeloma

KW - MM

KW - daratumumab

KW - newly diagnosed multiple myeloma

KW - lenalidomide discontinuation

U2 - 10.1016/S2152-2650(20)30491-2

DO - 10.1016/S2152-2650(20)30491-2

M3 - Conference abstract in journal

SN - 2152-2650

VL - 20

SP - S306-S307

JO - Clinical Lymphoma Myeloma and Leukemia

JF - Clinical Lymphoma Myeloma and Leukemia

IS - 1 supplement

M1 - MM-339

T2 - Society of Hematologic Oncology 2020 Annual Meeting

Y2 - 9 September 2020 through 12 September 2020

ER -